Aptose Biosciences is a science-driven biotechnology company advancing first-in-class therapeutics to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. The company is also creating proprietary companion diagnostic tools to identify predisposed sensitivities to targeted therapies for use in single-agent or combination regimens. Aptose Biosciences was founded in 1986 and is based in Toronto, Canada.
